## HSIC: Henry Schein, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -1.3% below STRENGTH zone (4.0-10.0%); PEG 1.71 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($70.36)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Norges Bank Invests $89.48 Million in Henry Schein, Inc. $HSIC**
- Source: MarketBeat | 20251205T111344 | Somewhat-Bullish | Relevance: 100%
- Norges Bank acquired a new stake in Henry Schein, Inc. (NASDAQ:HSIC) during the second quarter, purchasing 1,224,855 shares valued at approximately $89.48 million, representing about 1.01% of the company. Other institutional investors also adjusted their holdings in HSIC. Analysts have issued varied ratings and price targets for Henry Schein, with the company consistently topping earnings expectations and providing robust guidance for FY 2025.

**2. Hsbc Holdings PLC Raises Stake in Henry Schein, Inc. $HSIC**
- Source: MarketBeat | 20251204T140924 | Somewhat-Bullish | Relevance: 100%
- Hsbc Holdings PLC increased its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 15.9% during the second quarter, bringing its total to 155,065 shares valued at $11.33 million. The article notes that institutional investors now own 96.62% of the company, and Henry Schein recently surpassed quarterly earnings estimates with strong revenue and guidance for FY2025. Analysts currently maintain a "Hold" rating on the stock with an average price target of $76.17.

**3. How Investors May Respond To Henry Schein (HSIC) Gaining Exclusive U.S. Rights To Drill-Free Cavity Treatment**
- Source: Simply Wall Street | 20251204T062725 | Somewhat-Bullish | Relevance: 100%
- Henry Schein (HSIC) has secured exclusive U.S. distribution rights for vVARDIS's drill-free Curodont Repair Fluoride Plus product, expanding its role in preventive oral healthcare. This move, alongside advancements like VideaHealthâ€™s Detect AI, supports Henry Schein's strategy to shift towards higher-margin specialties and digital solutions. Despite these growth initiatives, investors should remain aware of ongoing price competition risks in core dental supplies.

**4. Skandinaviska Enskilda Banken AB publ Acquires 19,688 Shares of Henry Schein, Inc. $HSIC**
- Source: MarketBeat | 20251204T010951 | Somewhat-Bullish | Relevance: 100%
- Skandinaviska Enskilda Banken AB publ significantly increased its stake in Henry Schein, Inc. (NASDAQ:HSIC) by acquiring 19,688 shares, bringing its total to 19,851 shares valued at approximately $1.45 million. This move comes as analysts have a mixed "Hold" consensus for Henry Schein, with some firms raising their price targets, and the company recently beat Q earnings estimates and issued FY2025 guidance. Institutional investors now own 96.62% of the company's stock.

**5. Q3 Rundown: Henry Schein (NASDAQ:HSIC) Vs Other Dental Equipment & Technology Stocks**
- Source: Finviz | 20251203T223100 | Bullish | Relevance: 100%
- This article analyzes the Q3 2025 performance of Henry Schein (NASDAQ:HSIC) and its peers in the dental equipment and technology sector, highlighting strong overall results for the sector. Henry Schein reported revenues exceeding expectations, while Envista (NYSE:NVST) led in analyst estimates beat and revenue growth. Dentsply Sirona (NASDAQ:XRAY) showed the weakest performance, and Align Technology (NASDAQ:ALGN) also posted strong results, benefiting from recent economic stability and rate cuts.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 5, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-05 | JP Morgan | $78 | $76 | +3% |
| 2025-11-05 | Barrington Rese | $79 | $78 | +1% |
| 2025-11-05 | Morgan Stanley | $58 | $55 | +5% |
| 2025-11-05 | Wells Fargo | $76 | $70 | +9% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-05 | JP Morgan | main | Overweight |
| 2025-11-05 | Barrington Rese | main | Outperform |
| 2025-11-05 | Morgan Stanley | main | Underweight |
| 2025-11-05 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 5 ($0.15M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 64.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Kohlberg Kravis Robe: 13.3% (0.0%)
- JPMORGAN CHASE & CO: 10.6% (+98.6%)
- Vanguard Group Inc: 10.2% (-7.2%)
- Artisan Partners Lim: 5.8% (+5.7%)
- Blackrock Inc.: 5.7% (-8.6%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 5 raises (avg +5%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 1.71 elevated, pricing in significant growth expectations. Analyst sentiment positive (5 raises, avg +5%). Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.2B |
| Beta | 0.89 |
| 52W Range | $60.56 - $82.49 |
| Short Interest | 5.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.71 |
| Forward P/E | 13.9 |
| Current P/E | 15.0 |
| YoY Growth | 7.6% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 0.1% to -1.3% (-1.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.3pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.4%) - potential reversal signal. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 59. OFD pattern: +SLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.29% (CS: 43) | Neutral |
| RSI_14 | 59.2 | Neutral |
| MACD Histogram | -0.23 | Bearish |
| vs SMA20 | 1.010x | Above |
| vs SMA50 | 1.081x | Above |
| vs SMA200 | 1.064x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $73.62
- **Stop Loss:** $70.36 (4.4% risk)
- **Target:** $76.88 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 153
- **Position Value:** $11,263.86
- **Portfolio %:** 11.26%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-24 (Est: $1.30)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.28 | $1.38 | +7.9% |
| 2025Q2 | $1.19 | $1.10 | -7.6% |
| 2025Q1 | $1.11 | $1.15 | +3.6% |
| 2024Q4 | $1.21 | $1.19 | -1.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*